Thromb Haemost 2016; 115(06): 1229-1230
DOI: 10.1160/TH15-12-0976
Letters to the Editor
Schattauer GmbH

Normalised immune expression in remission of paediatric ITP

Margareta Jernås
1   Department of Clinical Chemistry and Transfusion Medicine, University of Gothenburg, Gothenburg, Sweden
,
Frida Strömberg Célind
2   Department of Paediatrics, The Queen Silvia’s Hospital for Pediatric and Adolescents, Gothenburg, Sweden
,
Intawat Nookaew
3   Comparative Genomics Group, Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee, USA
4   Department Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
,
Karin Mellgren
2   Department of Paediatrics, The Queen Silvia’s Hospital for Pediatric and Adolescents, Gothenburg, Sweden
,
Hans Wadenvik
1   Department of Clinical Chemistry and Transfusion Medicine, University of Gothenburg, Gothenburg, Sweden
,
Bob Olsson
5   Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden
› Author Affiliations
Further Information

Publication History

Received: 21 December 2015

Accepted after minor revision: 25 January 2016

Publication Date:
27 November 2017 (online)

 

 
  • References

  • 1 Harrington WJ. et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1-10.
  • 2 Olsson B. et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-1124.
  • 3 Cines DB, Schreiber AD. Immune thrombocytopenia. Use of a Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med 1979; 300: 106-111.
  • 4 Rodeghiero F. et al. Standardisation of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393.
  • 5 Neunert CE. et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood 2013; 121: 4457-4462.
  • 6 Jernas M. et al. MicroRNA regulate immunological pathways in T-cells in immune thrombocytopenia (ITP). Blood 2013; 121: 2095-2098.
  • 7 Spolski R, Leonard WJ. Interleukin-21: a doubleedged sword with therapeutic potential. Nat Rev Drug Discov 2014; 13: 379-395.
  • 8 Jones JL. et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-2061.
  • 9 Zhu X. et al. Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia. J Clin Immunol 2010; 30: 253-259.
  • 10 Kisand K. et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010; 207: 299-308.
  • 11 Gaffen SL. et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14: 585-600.
  • 12 Rocha AM. et al. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia. Haematologica 2011; 96: 1560-1564.
  • 13 Wang JD. et al. Reduced expression of transforming growth factor-beta1 and correlated elevation of interleukin-17 and interferon-gamma in paediatric patients with chronic primary immune thrombocytopenia (ITP). Paediatr Blood Cancer 2011; 57: 636-640.
  • 14 Belnoue E. et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008; 111: 2755-2764.